No DEA rescheduling action on psilocybin, MDMA, or ibogaine occurs despite the new FDA pick's advocacy.

Even though the new head of the FDA (the US drug regulator) publicly supports psychedelic medicines, actually moving these drugs to a less restricted legal category takes years of formal government steps — it requires sign-off from the Department of Health and Human Services plus a lengthy public rulemaking process. Talking favorably about psychedelics on a podcast does not skip any of those steps. Nothing changes on paper in 2026.

Scheduling requires an HHS recommendation plus rulemaking — a multi-year process. A podcast-friendly appointee doesn't shortcut Controlled Substances Act procedure.